Neurentis plc
Neurentis is a UK-based biotech company specializing in developing novel treatments for neurological and psychiatric disorders, particularly focusing on mental health. The company's strategy involves a low-risk commercial approach by licensing its products to global pharma companies. Their pipeline includes NRNT-012302 (Quivara™), a transdermal patch for Treatment-Resistant Depression in late-stage development, NRNT-012201 (Neurobiomod™), a natural formula for mental health support, and an AI-driven drug discovery initiative for depression. The company is led by experienced ex-pharma executives with over 30 years of sector experience and is supported by industry advisors. They aim to address unmet needs in a large and growing market, driven by increasing awareness and demand for effective mental health treatments.
Neurentis plc
Neurentis is a UK-based biotech company specializing in developing novel treatments for neurological and psychiatric disorders, particularly focusing on mental health. The company's strategy involves a low-risk commercial approach by licensing its products to global pharma companies. Their pipeline includes NRNT-012302 (Quivara™), a transdermal patch for Treatment-Resistant Depression in late-stage development, NRNT-012201 (Neurobiomod™), a natural formula for mental health support, and an AI-driven drug discovery initiative for depression. The company is led by experienced ex-pharma executives with over 30 years of sector experience and is supported by industry advisors. They aim to address unmet needs in a large and growing market, driven by increasing awareness and demand for effective mental health treatments.